18-07-2025
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel downgraded Clearside Biomedical (CLSD) to Hold from Buy with a price target of $2, down from $8. In a challenging financing environment, Clearside has arrived at the end of its cash runway with no new injection of capital and is now considering strategic alternatives, the analyst tells investors in a research note. The firm added that, given the company has been seeking capital influx for some time for further development of CLS-AX, the outcome of its new efforts to preserve cash and maximize the remaining value in its platform is uncertain.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
